AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – Patients with relapsed/refractory primary mediastinal large ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – The immune checkpoint inhibitor avelumab showed ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – Tazemetostat, a first-in-class experimental agent that ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – A combination of the Bruton’s tyrosine ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – A novel combination of the anti-programmed ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – The chemotherapy-free combination of lenalidomide (Revlimid) ...
AT 14-ICML Lugano, Switzerland (FRONTLINE MEDICAL NEWS)– It’s in the BAG: For patients with ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – For patients with relapsed or refractory ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – Combining lenalidomide (Revlimid) with an anti-CD19 ...
AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – A combination of ibrutinib and umbralisib, ...
FROM 13-ICML An international prognostic index for patients with chronic lymphocytic leukemia (CLL) may ...
FROM 13-ICML Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed ...
FROM 13-ICML A randomized trial designed to compare autologous to allogeneic stem cell transplantation ...